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Abstract 
Protein aggregation underlies an array of human diseases, yet only one small molecule therapeutic 
has been successfully developed to date. Here, we introduce an in vivo system, based on a E-
lactamase tripartite fusion construct, capable of identifying aggregation-prone sequences in the 
periplasm of Escherichia coli and inhibitors that prevent their aberrant self-assembly. We demonstrate 
the power of the system using a range of proteins, from small unstructured peptides (islet amyloid 
polypeptide and amyloid E to larger, folded immunoglobulin domains. Configured in a 48-well format, 
the split E-lactamase sensor readily differentiates between aggregation-prone and soluble sequences. 
Performing the assay in the presence of 109 compounds enabled a rank ordering of inhibition and 
revealed a new inhibitor of IAPP aggregation. This platform can be applied to both amyloidogenic and 
other aggregation-prone systems, independent of sequence or size, and can identify small molecules 
or other factors able to ameliorate or inhibit protein aggregation.  
  
1 
Introduction 
Preventing protein aggregation is of paramount importance in our quest to alleviate some of the most 
prevalent diseases in the developed world, from neurodegenerative disorders including Alzheimer’s 
and Parkinson’s diseases, to systemic disorders such as type II diabetes mellitus1. The key 
pathological hallmark of amyloid diseases is the accumulation of aggregated proteins in fibrillar 
structures known as amyloid2. The majority of studies of amyloid diseases suggest that the most toxic 
species are low molecular weight soluble oligomers, or higher molecular weight prefibrillar 
intermediates that form en route to fibrils2, although fibrils themselves may also play a contributing 
role3, 4.  
One approach to prevent protein aggregation is to bind small molecules specifically to the precursor 
protein of interest and hence inhibit the initial stages of misfolding and self-assembly5. As many 
aggregation-prone proteins are intrinsically disordered, structure-based design strategies are not 
always possible. Identification of small molecules that prevent protein aggregation by in vitro 
screening methods commonly requires the demanding purification of the aggregation-prone precursor 
protein in high yield for subsequent biophysical analysis, e.g. using the fluorescence of thioflavin T 
(ThT) or analysis by electron microscopy (EM) or other spectroscopic methods. Such analyses, 
however, are slow, laborious and can lead to false positive results6. Furthermore, synthetic peptide 
samples can be difficult to produce in a form that is free of oligomeric ‘seeds’ that can nucleate further 
aggregation7. The presence of these pre-existing oligomers during inhibitor screening could lead to 
some of the most important inhibitors, those that prevent low molecular weight oligomer formation, 
being overlooked. 
Here we describe a powerful sensor for detecting the aggregation of proteins into both amyloid and 
amorphous aggregates and its inhibition by small molecules. Taking the form of a E-lactamase 
tripartite fusion construct8, the sensor directly links the aggregation-propensity of a test protein in the 
periplasm of E. coli to a simple phenotypic readout: antibiotic resistance. We show that the system 
can be used to detect aggregation-prone sequences and to screen for inhibitors that prevent protein 
aggregation, using human and rat islet amyloid polypeptide (hIAPP and rIAPP, respectively), amyloid 
E 1–40 (AE40), amyloid E 1–42 (AE42), E2microglobulin (E2m) and its amyloid variant D76N and the 
domain antibodies HEL4 and Dp47d as examples. The in vivo system described enables facile 
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analysis of protein aggregation and its inhibition, without requiring any prior knowledge of the protein’s 
structure or function. 
 
Results 
Rationale for the periplasmic-based screen 
Previous studies have shown the potential of using bacterial- or yeast-based systems to screen for 
small molecule inhibitors of protein aggregation9-14. The systems reported to date, however, have 
been limited to the reducing environment of the cytosol, preventing analysis of disulfide bond-
containing proteins, which comprise ! 50  of proteins involved in pathologic amyloid disease1. 
Another critical limitation of cytoplasmic-based screens is the restrictive nature of biological 
membranes, limiting their application to the identification of molecules that can traverse this barrier. 
The work described here obviates these drawbacks by performing a screen for inhibitors of protein 
aggregation within the oxidizing periplasmic space of E. coli. Therein, disulfide bond formation is 
permitted and the presence of outer membrane porins allows diffusive access to molecules up to ~ 
600 Da15. In the aggregation sensor described, the test sequence is inserted between two domains of 
the periplasmic-based reporter enzyme TEM-1 E-lactamase (Figs. 1a, b). Upon correct folding of the 
test protein in the periplasm of E. coli, the two halves of E-lactamase are brought into close proximity 
and form a functional enzyme, enabling the bacteria to be resistant to E-lactam antibiotics (Fig. 1c). 
This E-lactamase tripartite fusion system has been used previously to identify protein variants with 
increased thermodynamic stability, to identify new periplasmic chaperones and to develop excipients 
that stabilize proteins thermodynamically8, 16, 17. The assumption of the assay described here is that if 
the test protein aggregates, the E-lactamase domains will be prevented from associating, andor the 
active enzyme will be removed from the periplasm by degradation, leading to E. coli with increased 
sensitivity to E-lactam-containing antibiotics (Fig. 1d). When the bacteria are grown in the presence of 
small molecule inhibitors of protein aggregation, antibiotic resistance should be restored in a 
quantitative manner (Fig. 1e).  
  
3 
Identification of aggregation-prone sequences 
To demonstrate that the antibiotic resistance conferred by the tripartite E-lactamase fusion sensor can 
be used to monitor protein aggregation in vivo, four test proteins with different aggregation 
propensities were selected: hIAPP, rIAPP, AE40 and AE42 (Supplementary Results, 
Supplementary Fig. 1a). AE40 and AE42, peptides involved in Alzheimer’s disease, are highly 
aggregation-prone and were chosen for analysis based on their rapid, in vitro aggregation rates18, 19. 
hIAPP, the aggregating protein in type II diabetes mellitus, shares 24  sequence identity and 46  
similarity with AE42 (Supplementary Fig. 1b) and is also highly aggregation-prone20. hIAPP also 
contains a disulfide bond that plays a role in the fibril assembly mechanism21. By contrast, rIAPP 
shares 84  sequence identity with hIAPP, but is not amyloidogenic20. This sequence thus provides a 
useful control for the aggregation screen.  
The antibiotic resistance conferred by the four E-lactamase test protein constructs was determined in 
a 48-well agar plate assay. The test proteins were cloned into a 28-residue glycineserine-rich linker 
(Ela-linkerSHORT) between residues 196 and 197 of TEM-1 E-lactamase (Figs. 1a, b, Supplementary 
Tables 1 and 2) and the antibiotic resistance of E. coli expressing each of the constructs was 
measured as the maximal cell dilution at which colony growth was observed to occur (MCDGROWTH, 
see online Methods) after 18 h over a range of ampicillin concentrations (0–140 PgmL). A non-
aggregating control (E-lactamase containing a 64-residue glycineserine linker, similar in length to the 
65–70 residue combined length of the AEIAPP-GS linker in the sensor constructs) was also analyzed 
(Ela-linker). The spot titers comparing the growth of the strains expressing the different constructs at a 
single concentration of ampicillin (80 PgmL) are depicted in Fig. 1f. The results showed that bacteria 
expressing the non-aggregating glycineserine-rich linker (Ela-linker) and rIAPP (Ela-rIAPP) constructs 
grew at significantly higher cell dilutions (Fig. 1f) and at higher concentrations of ampicillin (Fig. 1g) 
than the strains expressing the aggregating constructs (Ela-hIAPP, Ela-AE40 and Ela-AE42). As the 
glycineserine linker, rIAPP, hIAPP, AE40 and AE42 are all intrinsically disordered22, 23, the reduced 
enzymatic activity of E-lactamase presumably results from aggregation in vivo and cannot be 
attributed to the presence of an extended loop region separating the two domains of E-lactamase. 
Furthermore, the reduced E-lactamase activity observed for Ela-AE4042 and Ela-hIAPP cannot be 
explained by differential expression as Western blot analysis showed that all constructs expressed to 
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a similar level (Supplementary Fig. 2a). However, for all proteins except Ela-linker, the majority of the 
protein was insoluble (Supplementary Fig. 2b). The data show, therefore, that the split E-lactamase 
system can be used as a sensor for protein aggregation in vivo.  
 
Protein aggregation correlates with antibiotic resistance 
The extent of antibiotic resistance observed for the different E-lactamase constructs in vivo was next 
compared with the amyloid growth profile of the test peptides in vitro in the absence of the E-
lactamase scaffold. Thioflavin T (ThT) fluorescence over 24 h (Fig. 2a) and transmission electron 
microscopy (TEM) images (taken after 5 days of incubation, Fig. 2b) showed that amyloid fibrils were 
formed by hIAPP, AE40 and AE42, but not rIAPP, as expected18-20. These data show a correlation 
between the rate of amyloid formation observed by ThT fluorescence for the isolated peptides and the 
level of antibiotic resistance revealed by the in vivo sensor assay (compare Fig. 2a and Fig. 1g). 
Importantly, rIAPP, which does not form amyloid fibrils (Fig. 2a) but instead forms small spherical 
aggregates in vitro (Fig. 2b), did not result in significantly reduced antibiotic resistance (at ampicillin 
concentrations  60 PgmL) compared with the Ela-linker construct (Fig. 1g). Conversely, the three 
amyloidogenic peptides, hIAPP, AE40 and AE42, formed long straight fibrillar structures (Fig. 2b), and 
significantly reduced the ampicillin resistance of bacteria containing these sequences in the tripartite 
E-lactamase sensor (Fig. 1g).          
The progress of aggregation of each of the four peptides was also investigated using electrospray 
ionisation-mass spectrometry linked to ion mobility spectrometry (ESI-IMS-MS)24. The resulting 
Driftscope plots represent a snap-shot of the species present in solution at a given time point during 
the aggregation process. At t   2 min, monomeric through to hexameric species were observed for 
both rIAPP and hIAPP, consistent with previous results (Fig. 2c)20. The intensity of these oligomers 
remained similar after 24 h (Fig. 2d), suggesting that although aggregation is occurring (into low-order 
aggregates or fibrils, for rIAPP and hIAPP, respectively), the reaction had not yet reached completion. 
In the case of AE40, at t   2 min monomeric through to pentameric species were observed (Fig. 2c). 
After 24 h, the rapid aggregation of this peptide resulted in the consumption of higher order species 
such that only monomer through to trimer remained (Fig. 2d). For AE42, the most aggregation-prone 
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of the four peptide sequences studied18, aggregation occurred at such a rate that oligomers were 
difficult to observe by ESI-IMS-MS. As early as t   2 min (Fig. 2c), no higher order (! tetrameric) 
oligomers were observed under the conditions of this experiment, with only monomers and dimers 
remaining after 24 h (Fig. 2d).  
The data reveal a correlation between the in vivo antibiotic sensitivity of each E-lactamase construct 
and the aggregation propensity of the test peptides in vitro. To determine the effect of the 
incorporation of the peptide sequences into the E-lactamase scaffold on their aggregation propensity 
in vitro, Ela-hIAPP and Ela-linker were expressed recombinantly and the ability of the resulting purified 
proteins to aggregate was measured. After 5 days incubation, 66  of Ela-hIAPP could be pelleted by 
centrifugation (Fig. 3a) and the specific enzyme activity of the whole sample had decreased by 74  
(Fig. 3b, specific activity at 0 days   226 r 9 Pmolminmg enzyme, defined as 100 ). The data 
demonstrate, therefore, that insertion of the hIAPP sequence causes the aggregation of the E-
lactamase construct, rendering it inactive. The aggregates formed by Ela-hIAPP in vitro are amyloid-
like, demonstrated by binding of the amyloid-specific dyes NIAD-425 and ThT (Supplementary Fig. 
3a, b), their appearance as long, straight fibrils, observed by negative-stain TEM (Supplementary 
Fig. 3c), and recognition by the amyloid fibril-specific antibody WO126 (Supplementary Fig. 3d). 
Notably, no aggregation or amyloid formation was detected under the same conditions for the Ela-
linker construct (Figs. 3a, b and Supplementary Fig. 3). This demonstrates that although the termini 
of hIAPP are joined to the E-lactamase linker, the hIAPP sequence is still able to cause amyloid 
formation of the intact Ela-hIAPP construct.  
We next examined the ability of the tripartite fusion system to distinguish between aggregation-prone 
and aggregation-resistant proteins using the larger, globular disulfide bond-containing immunoglobulin 
(Ig) domain of wild-type (WT) human E2m and its naturally occurring variant D76N (11.9 kDa, 100 
residues) (Supplementary Fig. 4a). WT E2m does not form amyloid fibrils in vitro at neutral pH27, 
whereas D76N E2m readily aggregates and causes systemic amyloid disease28, 29. In addition, the 
effect of the insertion of biopharmaceutically-relevant domain antibodies (dAbs) on antibiotic 
resistance was also examined, by the creation of constructs containing the soluble dAb HEL4 (12.9 
kDa, 120 residues) and its aggregation-prone counterpart, Dp47d (a human VH dAb encoded by the 
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same germline gene as HEL4 but differing in 41 residues; 12.4 kDa, 116 residues)30 (Supplementary 
Fig. 4b). Unlike the other test proteins selected, Dp47d rapidly aggregates in vitro into amorphous 
aggregates31. The antibiotic resistance of bacteria expressing either of the aggregation-prone variants 
(Ela-E2m-D76N or Ela-Dp47d) was significantly lower at all ampicillin concentrations studied than their 
non-aggregating counterparts (Supplementary Fig. 4c, d). The data demonstrate the capability of 
the tripartite fusion system to detect aggregation- and non-aggregation-prone variants ranging in size 
(3.9–12.9 kDa), structure (natively disordered or folded), and aggregation properties (amyloid versus 
non-specific aggregation). Previous studies using the tripartite system described to evolve protein 
stability in vivo have demonstrated the ability to insert larger proteins (maltose binding protein, 
42.5 kDa) into the linker region of E-lactamase8, indicating that the system could be used for even 
larger aggregation-prone variants than those demonstrated in this study.   
 
Protein aggregation inhibitors rescue bacterial growth 
To demonstrate that the E-lactamase tripartite sensor can be used as a screen for small molecule 
discovery, the in vitro aggregation experiments using Ela-hIAPP were repeated in the presence of a 
10-fold molar excess of the known inhibitor of hIAPP aggregation, curcumin32, 33 (compound 1, 
Supplementary Data Set 1, Supplementary Table 3). This compound prevented Ela-hIAPP 
aggregation in vitro, as indicated by retention of Ela-hIAPP in solution in a catalytically active form 
(Figs. 3b, c). Importantly, the control Ela-linker did not aggregate in the absence or presence of 
curcumin (Fig. 3a, c), and the presence of curcumin did not affect the specific activity of this non-
aggregating control (Fig. 3b). The ability of Ela-hIAPP to bind curcumin was corroborated further by 
ESI-MS (Supplementary Fig. 5), and TEM analysis of the samples at the end of the 5 day incubation 
showed a lack of fibrillar material in the presence of curcumin, but not in its absence (Fig. 3d). The 
ability of curcumin to prevent Ela-hIAPP aggregation in vivo was then demonstrated by increased 
maximal cell dilution allowing growth (MCDGROWTH) values over a range of ampicillin concentrations 
(0–140 PgmL) (Fig. 3e), once the effect of curcumin on bacterial growth was accounted for (using the 
non-aggregating control Ela-linker, see online Methods and Supplementary Fig. 6). To obtain a 
single value that showed the effect of the small molecule on bacterial growth, the ratio of the 
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MCDGROWTH values of the treated versus untreated samples was calculated from the area under the 
antibiotic survival curves and plotted as log2(treateduntreated) (Fig. 3f). This approach identifies any 
small molecule with a log2 score ! zero as a ‘hit’ in the in vivo screen, with full (100 ) rescue of 
bacterial growth for Ela-hIAPP compared with Ela-linker giving a log2(treateduntreated) score of 1.2. 
The results show, therefore, that growth of Ela-hIAPP-expressing bacteria is restored in the presence 
of curcumin in a dose-dependent manner, with full rescue from Ela-hIAPP aggregation occurring at ! 
200 PM curcumin (Fig. 3f). 
 
System detects inhibitors of hIAPP aggregation in vivo 
Having established a system capable of detecting inhibition of Ela-hIAPP aggregation in vivo, we next 
built on our previous results (using a synthetic peptide of hIAPP)24 by repeating the in vivo sensor 
assay in the presence of nineteen additional small molecules with known effects on the aggregation of 
hIAPP (Supplementary Table 3, compounds 2–20; Supplementary Data Set 1). Five of these 
molecules (acid fuchsin34, 35, EGCG20, 24, 36, Fast green FCF24, 35, caffeic acid37 and silibinin20, 38), 
together with curcumin32, 33, have been shown to inhibit hIAPP amyloid formation in vitro, ten 
compounds (hemin24, resveratrol39, 1H-B-SA24, benzimidazole24, tramiprosate24, aspirin24, Congo 
red24, azure A, thiabendazole and Orange G (Supplementary Table 3)) do not prevent hIAPP 
aggregation, and four compounds (acridine orange40, myricetin41, 42, phenol red43, 44 and morin 
hydrate45) have been suggested as inhibitors of hIAPP aggregation in vitro, but with either incomplete 
or equivocal results. A concentration of 100 PM small molecule was chosen to minimize any inherent 
cellular toxicity of the compounds and the log2(treateduntreated) scores were calculated (Fig. 4a). 
Five of the published inhibitors of hIAPP aggregation (curcumin, acid fuchsin, EGCG, Fast green FCF 
and caffeic acid), and one compound with conflicting results (acridine orange), were clear hits in the in 
vivo screen (Fig. 4a). The single false negative observed in the screen was the small molecule 
silibinin which inhibits hIAPP aggregation in vitro20, but had no protective effect in the in vivo assay 
(Fig. 4a). However, when the concentration of silibinin was increased, Ela-hIAPP aggregation was 
prevented in vivo (Supplementary Fig. 7a). By contrast, increasing the concentration of a compound 
that had no effect on bacterial growth at 100 PM (benzimidazole) up to 1,000 PM did not rescue 
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bacterial sensitivity to ampicillin (Supplementary Fig. 7b). Two compounds (myricetin and phenol 
red) were partial hits, while the remaining eleven molecules had no restorative effect on cell growth 
(Fig. 4a). It is noteworthy that log2(treateduntreated) scores in the presence of the latter set of 
compounds are negative. This suggests that the effects of aggregation and ampicillin on cell viability 
are not independent. 
The in vitro aggregation propensity of hIAPP peptide in the absence (Fig. 4b) or presence (Fig. 4c–f, 
Supplementary Table 4) of each of the twenty small molecules tested was also investigated using 
ESI-IMS-MS20, 24 and TEM. In the absence of small molecule inhibitors of aggregation, hIAPP formed 
up to hexameric oligomers (within 2 min of dilution into buffer), as observed by ESI-IMS-MS20, 24 (Fig. 
4b Driftscope), and fibrils were observed after 5 days incubation (Fig. 4b TEM). Five ‘hits’ from the in 
vivo screen (curcumin, acid fuchsin, EGCG, Fast green FCF and acridine orange) bound to hIAPP 
specifically at a 10-fold molar excess (Fig. 4c and Supplementary Table 4 ESI mass spectra), 
prevented or retarded oligomer formation (Fig. 4c Driftscope, Supplementary Table 4) and inhibited 
fibril formation (Fig. 4c TEM, Supplementary Table 4). The partial hits from the in vivo screen, 
myricetin and phenol red, bound non-specifically (multiple ligands bound) to hIAPP and did not 
prevent formation of aggregated material (Fig. 4d and Supplementary Table 4). Conversely, the 
twelve small molecules that failed to prevent Ela-hIAPP aggregation in the in vivo screen (Fig. 4a) 
either did not bind (Fig. 4e), or bound non-specifically or colloidally (self-association of small 
molecule, Fig. 4f) to hIAPP in vitro, resulting in the formation of amyloid fibrils or large amorphous 
aggregates (Figs. 4e, 4f, Supplementary Table 4). Similar results were obtained using Ela-hIAPP in 
the presence of the same small molecules (Fig. 4b–f TEM).  
 
Screen identifies a new inhibitor of hIAPP aggregation  
The screen detailed above was performed in 48-well agar plate format and requires ~ 0.5 mg small 
molecule per assay. To increase throughput and to minimize the amount of small molecule required 
the screen was repeated, using the same twenty test molecules, at a single concentration of ampicillin 
(100 PgmL) and small molecule (100 PM), thereby requiring only ~ 0.07 mg of compound (online 
Methods and Supplementary Fig. 8). Any intrinsic effect of each small molecule on bacterial growth 
was accounted for by determining the effect of the same concentration of small molecule on the 
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growth of Ela-linker at 100 PgmL ampicillin. Consistent with the results in Fig. 4a, the same six small 
molecules able to prevent Ela-hIAPP aggregation were identified using the miniaturized assay 
(Supplementary Fig. 9, compounds 1–6). To further demonstrate the feasibility of a larger scale 
screen, an additional thirty compounds that we have previously shown to inhibit or have no effect on 
hIAPP aggregation in vitro using ESI-MS and TEM24 were screened in the miniaturized in vivo assay 
using an ampicillin concentration of 100 PgmL (Supplementary Data Set 1, Supplementary Fig. 9, 
compounds 21–50). The results were entirely consistent between the in vitro and in vivo assays with 
only one small molecule previously shown to bind specifically to hIAPP (using ESI-MS) and prevent 
fibril formation in vitro24 resulting in a positive score in the in vivo assay (compound 36, named here 
JCS-1).  
In the quest to identity a new inhibitor of hIAPP aggregation, an additional fifty-nine compounds were 
chosen to assay against hIAPP aggregation in vivo. Thirty-one of the chosen compounds are known 
to interact with, andor prevent, aggregation of other proteins (Supplementary Data Set 1 
compounds 51–81) and a further twenty-eight compounds were selected through focused screening 
using Rapid Overlay of Chemical Structures (ROCS), a method that improves the hit-rate of high 
throughput screening (HTS) (Supplementary Data Set 1 compounds 82–109). These compounds 
were selected for analysis based on their structural similarities to the inhibitor of hIAPP aggregation 
identified previously, JCS-1 (compound 36)24. From these fifty-nine compounds, one compound 
significantly aided growth (compound 56 (dopamine); Supplementary Figs. 10 and 11; 
log2(treateduntreated)   0.75), while five compounds were identified which moderately aided bacterial 
growth (log2(treateduntreated)   0.24; compounds 52 (apomorphine), 84 (JCS-2), 94 (JCS-3), 100 
(JCS-4) and 103 (JCS-5); Supplementary Fig. 10). The ability of the five moderate hit compounds to 
prevent hIAPP aggregation was confirmed by analysis of increasing concentrations of each small 
molecule on bacterial growth (Supplementary Fig. 12), combined with TEM (Supplementary Fig. 
12) and ESI-IMS-MS analysis (Supplementary Fig. 13). When the in vivo assay was repeated over 
the original full range of ampicillin concentrations (0–140 PgmL) in the presence of increasing 
concentrations of the strong hit dopamine, bacterial growth was rescued in an approximately dose-
dependent manner (Fig. 5a, b). Dopamine is known to reduce fibril formation of AE46 and D-synuclein 
(the protein associated with Parkinson’s disease)46, 47 by driving the aggregation pathway towards the 
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formation of non-fibrillar oligomers or small protofilaments. hIAPP treatment with a 10-fold excess of 
dopamine led to the formation of small amorphous aggregates (Fig. 5c) and ESI-IMS-MS analysis 
confirmed that dopamine binds specifically to hIAPP (Fig. 5d), preventing high order oligomer 
formation (Fig. 5e). 
Finally, the hydrophobicity (LogP, the logarithm of the hydrophobic partition coefficient) and molecular 
weight of the newly identified small molecule inhibitors were compared with all other small molecules 
in our screen. Importantly, the results (Supplementary Figs. 14 and 15) showed that the in vivo 
assay does not simply identify small or hydrophobic compounds. In addition, analysis of the properties 
of these compounds as pan-assay interference compounds (PAINS), small molecules that can lead to 
aberrant identification of leads based on promiscuous binding, covalent modification of the target, 
small molecule reactivity, chemical aggregation or fluorescence48, 49, identified two of the five newly 
identified inhibitors as potential PAINS molecules (apomorphine and dopamine, compounds 52 and 
56, respectively; Supplementary Data Set 1). Importantly, by analyzing all of the compounds from 
our in vivo screen using ESI-IMS-MS (Supplementary Table 4 and Supplementary Fig. 13) we are 
able to rule out any degradation of the compound, covalent attachment or chemical modification of 
hIAPP based upon the mass of each species present.    
 
Discussion  
Current in vitro techniques for investigating protein aggregation and its inhibition can be costly, time 
consuming and require large quantities of often difficult to purify proteins. Here, we describe a facile 
approach for screening protein aggregation propensity and its inhibition in the periplasm of E. coli. 
The system has multiple benefits: i) it is able to detect and quantify the extent of protein aggregation 
in vivo via a simple readout of antibiotic resistance; ii) it can be used to screen for inhibitors of 
aggregation; and iii) it is applicable to proteins of different sizes and structure, with or without disulfide 
bonds and different aggregation propensities (amyloid or non-specific aggregation into large 
assemblies). We show that the system reports reliably on the aggregation of four test proteins that are 
intrinsically disordered (rIAPP, hIAPP, AE40 and AE42) and four that are stably folded Ig domains (WT 
E2m, D76N E2m, HEL4 and Dp47d).  
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A powerful use of the periplasmic-based assay described is its ability to screen for small molecule 
inhibitors of aggregation. Here, we demonstrate this principle by describing a selection of 109 small 
molecules against the aggregation of hIAPP, both in vivo and in vitro. To enable large pools of 
potential aggregation inhibitors to be screened against a protein target, we have also miniaturized the 
assay to make it amenable to high throughput format, using just ~ 0.07 mg of test compound. Indeed, 
this enabled the discovery of dopamine as an inhibitor of hIAPP aggregation.  
The ability to distinguish aggregation-prone variants from their non-aggregating counterparts in vivo 
suggests that the system developed could be used to study the aggregation propensity of mutants of 
aggregation-prone proteins without the requirement to first purify each variant. As the readout of the in 
vivo assay is independent of the activity, size or structure of the inserted test protein, it obviates the 
need to develop individual assays for different test proteins to determine their aggregation levels. The 
tripartite sensor also avoids the use of ThT, which can lead to erroneous results6. The tripartite 
system described here has previously been used to evolve protein stability in vivo, which 
demonstrated the ability to insert large proteins (maltose binding protein, 43 kDa) into the linker region 
of E-lactamase8. In combination with the data presented here, this validates the utility of the assay for 
analysis of large protein systems, as well as proteins that are intrinsically disordered or initially folded, 
as well as for proteins that form ordered aggregates such as amyloid, or form amorphous aggregates, 
including  candidate biopharmaceuticals. Whether the system can also detect aggregation into 
oligomers for different systems, including those proposed to be cytotoxic, remains to be determined. 
However, the observation that bacteria expressing Ela-rIAPP grow OHVVZHOOWKDQȕOD-linker (at ! 60 
PgmL ampicillin, Fig. 1g), suggests that small oligomeric states may indeed impart a deleterious 
effect on E-lactamase activity in the absence of large aggregates. This difference in growth is more 
pronounced at higher concentrations of ampicillin than used in this study, demonstrating that tuning of 
the ampicillin concentration range for the aggregating system of interest may enable identification of 
smaller aggregated species than those shown here. As with other screening techniques for small 
molecule inhibitors of protein aggregation, it is essential to analyse potential hits from the in vivo 
screen using additional biophysical analyses. Here we show the powers of ESI-IMS-MS for such 
analysis in its capability not only to distinguish specific from non-specific or colloidal binding24, but 
also to determine the effect of ligand binding on the oligomeric species formed. The in vivo sensor, in 
conjunction with ESI-IMS-MS and TEM, could also be used, therefore, to identify compounds that 
12 
arrest aggregation at different assembly stages, providing novel compounds with defined properties 
for the determination of toxic or benign intermediate species. 
The inherent ability of proteins to aggregate into amyloid fibrils underlies more than fifty human 
diseases1. With our ageing population, the social and economic burdens on patients and society are 
expected to increase dramatically over the coming years. To date, only one successful small molecule 
therapeutic targeting an amyloid disease has been developed5. As the complex nature of these 
diseases may demand a multi-pronged attack, identification of protein aggregation inhibitors is a vital 
step towards therapeutic alleviation of these devastating diseases. Moreover, at a fundamental level, 
the discovery of small molecules able to trap aggregating proteins at defined points, made possible by 
combining the tripartite system and ESI-IMS-MS analysis, will provide new opportunities to 
understand how and why proteins form amorphous aggregates or self-assemble into amyloid. We 
envisage, therefore, that the E-lactamase tripartite fusion system will play a valuable role in our quest 
to develop small molecules able to arrest amyloid formation, as well as to prevent aggregation of 
other valuable proteins, including protein-based pharmaceuticals.  
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Figure Legends 
Figure 1. Split E-lactamase assay for protein aggregation identifies aggregation-prone sequences. (a–
e) Schematic of the split E-lactamase assay for protein aggregation. (a) The test protein (green) is 
inserted into a glycineserine-rich linker (blue) within the loop region separating the two domains of 
TEM-1 E-lactamase (purple and pink). (b) Topology of TEM-1 E-lactamase highlighting the insertion 
point (green arrow) of the glycineserine-rich linker between residues 196 and 197 (figure created 
using online database PDBsum and PDB entry 1BTL50). (c) Association of the two E-lactamase 
domains results in the formation of the enzyme active site. (d) If the test protein aggregates, the 
activity of E-lactamase is reduced and the bacteria become more sensitive to E-lactam antibiotics. (e) 
Small molecule inhibitors (yellow) of protein aggregation diffuse into the periplasm via porins and 
prevent aggregation of the E-lactamase tripartite fusion protein, restoring bacterial resistance to E-
lactam antibiotics. (f) Spot titer of bacteria expressing Ela-linker (black), Ela-rIAPP (green), Ela-hIAPP 
(orange), Ela-AE40 (purple) or Ela-AE42 (pink) on agar containing 80 PgmL ampicillin. (g) Antibiotic 
survival curve of the maximal cell dilution allowing growth (MCDGROWTH) after 18 h over a range of 
ampicillin concentrations for each of the tripartite fusion constructs, colored as in (f). Data represent 
mean valuesr  s.e.m (n   4 replicate experiments). The arrow depicts the ampicillin concentration 
used in (f). 
 
Figure 2. Antibiotic resistance of the tripartite fusion constructs correlates with peptide aggregation 
propensity in vitro. ThT fluorescence intensity (a), negative stain TEM images (b) and ESI-IMS-MS 
Driftscopes taken at 2 min (c) or 24 h (d) of aggregates formed by rIAPP, hIAPP, AE40 and AE42. 
ThT fluorescence measured over 24 h. TEM images acquired after 5 days. Scale bar   100 nm. 
Driftscope plots (drift-time vs. mz vs. intensity) show extent of oligomerization after 2 min or 24 h. The 
numbers on the Driftscope plots indicate the oligomer order and the adjacent superscript numbers 
show the charge state of those ions.  
 
Figure 3. Ela-hIAPP aggregation in vitro and the effects of curcumin in vitro and in vivo. (a) 
Concentration of Ela-linker or Ela-hIAPP in the pellet (turquoise) or supernatant (SN, pink) after 5 
18 
days. (b) Specific enzyme activity (Pmol nitrocefin hydrolyzed per min per mg of enzyme) of the whole 
sample at the end of the 5 day incubation r a 10-fold molar excess of curcumin (32:320 PM). Specific 
activity at 0 days is defined as 100 . Data are presented as mean values r s.e.m, n   4 independent 
experiments. (c) Concentration of Ela-linker or Ela-hIAPP in the pellet or SN after 5 days incubation in 
the presence of a 10-fold molar excess of curcumin (structure inset). (d) TEM analysis of aggregates 
formed by Ela-linker or Ela-hIAPP r curcumin after the 5 days incubation (scale bar   100 nm). (e) 
Antibiotic survival curve showing the maximal cell dilution allowing growth (MCDGROWTH) of bacteria 
expressing the Ela-hIAPP construct in the presence of increasing concentrations of curcumin (0–500 
PM) (n   4 replicate experiments). Data were plotted after toxicity of curcumin was accounted (see 
online Methods and Supplementary Fig. 6). (f) Data plotted as log2(treateduntreated) growth, 
calculated from the areas under the antibiotic survival curves in (e); see online Methods equation (1). 
Center line   median; box limits   25th and 75th percentiles (whiskers extending to r 1.5u IQR), n   4. 
100  rescue is equivalent to log2(treateduntreated)   1.2 (indicated by dotted line). 
 
Figure 4. In vivo screen identifies hIAPP aggregation inhibitors. (a) Effect of 100 PM small molecule 
on bacterial growth, quantified by log2(treated untreated) (n   4). Data were calculated from the areas 
under the antibiotic survival curves, after the toxicity of the small molecule on bacterial growth was 
accounted for by analysis of the effect of each small molecule on the growth of cells expressing Ela-
linker (online Methods and Supplementary Fig. 6). Center line   median; box limits   25th and 75th 
percentiles (whiskers extending to r 1.5 u IQR). Black line indicates separation of hits (! 0, yellow) 
from non-hits ( 0, grey). In this format, 100  rescue is equivalent to log2(treateduntreated)   1.2. 
(b–f) ESI-MS mass spectra (left), IMS-MS Driftscope plots (middle) and negative statin TEM images 
(middle-right) of hIAPP peptide in the absence (b) or presence of acid fuchsin (c), phenol red (d), 
thiabendazole (e) or Orange G (f). Positive ion ESI mass spectra label Xy denotes the oligomer order 
(X) and charge state of the species (y). Xy  nL denotes the number (n) of ligands (L) bound to the 
particular Xy charge state. (b–e, far-ULJKW1HJDWLYHVWDLQ7(0LPDJHVRIDJJUHJDWHVIRUPHGE\ȕOD-
hIAPP r the same small molecules. TEM images taken after 5 days incubation. Scale bar   100 nm.  
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Figure 5. Identification of dopamine as an inhibitor of hIAPP aggregation. (a) Antibiotic survival curve 
showing the effect of dopamine (0–400 PM) on growth of bacteria expressing the Ela-hIAPP construct 
(n   4 replicate experiments). (b) Data plotted as log2(treateduntreated), calculated from the areas 
under the antibiotic survival curves in (b); see online Methods, equation (1). Center line   median; box 
limits   25th and 75th percentiles (whiskers extending to r 1.5 u IQR). In this format, 100  rescue is 
equivalent to log2(treateduntreated)   1.2 (indicated by dotted line). (c) Negative stain TEM analysis 
of aggregates formed by hIAPP r dopamine after 5 days incubation. Scale bar   100 nm. (d) ESI 
mass spectra showing hIAPP alone (i) or in the presence of a 10-fold excess of dopamine (structure 
inset). (e) ESI–IMS–MS Driftscope plots of hIAPP r dopamine. The numbers on the Driftscope plots 
indicate the oligomer order and the adjacent superscript numbers show the charge state of those 
ions. White circle indicates dopamine bound to hIAPP.  
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Online Methods 
Small molecules 
All small molecules were ! 98  pure and were purchased from Sigma-Aldrich Co. Ltd, except for 4,5-
dihydroxy-2,7-naphthalenedisulfonic acid, acid fuchsin, acridine orange, calmagite, Fast green FCF, 
methyl yellow, phenol red and rhodamine B (Fisher Scientific); and Basic blue 41, resveratrol and 
tramiprosate (Santa Cruz Biotech). The 28 compounds selected using ROCS Combiscore were 
obtained from an in-house library of small molecules at the University of Leeds, UK and were ! 95  
pure (by LCMS and 1H NMR analysis). 
 
Cloning test proteins into E-lactamase linker 
Plasmids containing the genes encoding E-lactamase with a 28-residue glycineserine (GS)-rich 
linker (pMB1-Ela-linkerSHORT) and E-lactamase with a 64-residue GS linker (pMB1-Ela-linkerLONG) were 
kindly provided by Prof. Jim Bardwell (Department of Biological Chemistry, University of Michigan, 
USA)8.  
Genes encoding the test proteins were cloned into the 28-residue GS linker that had previously been 
inserted between residues 196 and 197 of TEM-1 E-lactamase8 (Supplementary Table 1). PCR was 
performed to amplify the hIAPP, rIAPP, AE42 and WT-E2m genes from the plasmids pTXB1-hIAPP51, 
pTXB1-rIAPP51 (both kindly provided by Prof. Andrew Miranker, Yale University), pRSET-AE404252 
(kindly provided by Prof. Sarah Linse, Lund University) and pET23a-WT-E2m53. The primers were 
designed to encode XhoI and BamHI restriction sites 5ƍ and 3’ to the genes, respectively (see 
Supplementary Table 2 for primers) as these are the restriction sites in Ela-linkerSHORT. Synthetic 
genes encoding HEL4 or Dp47d with an XhoI restriction site 5ƍ and BamHI restriction site 3’ to the 
genes were purchased from Eurofins Genomics. The plasmids containing Ela-linkerSHORT, HEL4 and 
Dp47d, and the PCR products were digested with XhoI and BamHI. The sequences encoding the test 
proteins were ligated into the E-lactamase linker region and the ligation products were transformed 
into E. coli SCS1 cells (Stratagene) and the cells grown on agar plates containing 10 PgmL 
tetracycline. Successful ligation was identified by the resistance to tetracycline obtained from the 
vector. Plasmid DNA was purified from a selection of colonies and was sequenced to confirm that 
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plasmids contained the correct sequences. Primers for the sequencing reactions were designed to 
bind upstream and downstream of the GS linker of E-lactamase (Supplementary Table 2). The newly 
synthesized plasmids were named Ela-hIAPP, Ela-rIAPP, Ela-AE42, Ela-WT-E2m, Ela-HEL4 and Ela-
Dp47d. The plasmid Ela-AE40 was created using QuikChange mutagenesis (Agilent Technologies) by 
deleting the last two residues of the AE42 sequence that had been inserted into the E-lactamase linker 
(Supplementary Table 2). The plasmid Ela-E2m-D76N was created, using QuikChange mutagenesis, 
from the WT-E2m sequence that had been inserted into the E-lactamase linker (Supplementary Table 
2). 
 
MCDGROWTH assays 
Spot titer tests 
Spot titer tests were performed to determine the level of E-lactam antibiotic resistance of cells 
expressing the E-lactamase tripartite fusions. A single colony from fresh E. coli BL21 (DE3) cells 
(Stratagene) (transformed with the appropriate plasmid) was used to inoculate 100 mL sterile LB 
containing 10 PgmL tetracycline (Formedium). Cultures were incubated overnight at 37 qC with 
shaking (200 rpm). 1 mL of overnight culture was used to inoculate 100 mL sterile LB containing 10 
PgmL tetracycline and grown at 37 qC (shaking at 200 rpm) until an OD600 of 0.6 was reached. 
Expression of the E-lactamase fusion construct was induced by the addition of filter-sterilized 
arabinose (Sigma) to a final concentration of 0.02  (wv). Cultures were incubated for a further 1 h, 
when the OD600 of the cells was adjusted to 1.0 using sterile LB, and the cultures were then serially 
diluted in 10-fold increments into sterile 170 mM NaCl solution. 3 PL of each dilution was then spotted 
onto LB agar plates, supplemented with 10 PgmL tetracycline, 0.02  (wv) arabinose, and 
increasing concentrations of ampicillin (Formedium) (0–140 PgmL). The plates were incubated at 37 
qC for 18 h and the maximal cell dilution allowing cell growth (MCDGROWTH) was determined for each 
ampicillin concentration by visual inspection.  
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MCDGROWTH assay - full ampicillin range 
Assays were performed in 48-well agar plates (Greiner Bio-One). 48-well plates containing the small 
molecule of interest were prepared prior to the assay using the following procedure. Two plates were 
prepared for each small molecule of interest, one for bacteria expressing the Ela-linkerLONG construct 
and one for bacteria expressing the Ela-hIAPP construct. 3 PL of 10 mM small molecule (dissolved in 
DMSO, H2O, or EtOH) was added to each well of two 48-well plates. Tetracycline (10 PgmL final 
concentration) and filter sterilized arabinose (0.02  wv final concentration) were added to 100 mL of 
sterile 1.5  (wv) agar cooled to  50 qC. 297 PL of this solution was then added into each of the first 
6 wells (first row) of both 48-well plates. Plates were shaken (manually) to ensure mixing of the agar 
and small molecule. Ampicillin (10 mgmL stock) was then added to the agar stock to give the 
required concentration for the next row of wells. This procedure was repeated until the plate contained 
8 rows of agar containing increasing concentrations of ampicillin from 0–140 PgmL (20 PgmL 
increments). Agar plates were left to set in a sterile environment. The same procedure was followed 
to produce an additional two plates containing no small molecule (3 PL of solvent was added to the 
wells in place of small molecule).  
E. coli BL21 (DE3) cells transformed with the appropriate plasmid were grown as described above 
until an OD600 of 0.6 was reached. E-lactamase expression was then induced by the addition of filter-
sterilized arabinose to a final concentration of 0.02  (wv). 396 PL was removed and added to a 1.5 
mL Eppendorf tube containing 4 PL of 10 mM small molecule (to give a final small molecule 
concentration of 100 PM). These cultures were incubated for a further 1 h, when the OD600 of the cells 
was adjusted to 1.0 with LB medium and the culture then serially diluted 10-fold into sterile 170 mM 
NaCl solution. 3 PL of each dilution was then spotted onto the agar plates supplemented with the 
small molecule. The plates were incubated at 37 qC for 18 h and the MCDGROWTH was determined for 
each ampicillin concentration.  
The intrinsic effect of each small molecule on bacterial growth was determined by comparing the 
growth of E. coli BL21 (DE3) cells transformed with Ela-linker in the absence or presence of each 
small molecule. The effect of each small molecule on bacterial growth was subtracted from the E-
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lactamase-test protein assay, at each concentration of ampicillin. Example data are given in 
Supplementary Fig. 6. 
In order to obtain a single value from each MIC assay, illustrative of the small molecule’s effect on 
bacterial growth, the area under the MIC assay curves was calculated as a sum of the areas of 7 
trapezia using equation (1), where ܣ௖௨௥௩௘ is the total area under the curve, and ݔ௜ and ݕ௜ are the ݔ-
axis and ݕ-axis values at each concentration of ampicillin. 
        ࡭ࢉ࢛࢘࢜ࢋ = σ ࢟࢏ା࢟࢏శ૚૛ × (࢞࢏ା૚ െ ࢞࢏)ૠ࢏ୀ૚   Equation 1 
 
MCDGROWTH assay – HTS format 
Assays were performed in 48-well agar plates using a single concentration of small molecule (100 
PM) and ampicillin (100 PgmL). Supplementary Fig. 8 shows a summary schematic of the 
technique. 48-well agar plates containing the small molecule of interest were prepared prior to the 
assay using the same technique described above, however ampicillin (100 PgmL final concentration) 
was added to the agar prior to pouring the plates. Cultures were prepared as described previously. 
 
In vivo Western blot 
A single colony from fresh E. coli BL21 (DE3) cells (transformed with the appropriate plasmid) was 
used to inoculate 100 mL sterile LB containing 10 PgmL tetracycline. Cultures were incubated 
overnight at 37 qC with shaking (200 rpm). 1 mL of overnight culture was used to inoculate 100 mL 
sterile LB containing 10 PgmL tetracycline and grown at 37 qC (shaking at 200 rpm) until an OD600 of 
0.6 was reached. 10 mL of culture was removed for the uninduced sample and centrifuged at 4,000 g 
for 10 min (4 qC). Expression of the E-lactamase fusion construct was induced by the addition of filter-
sterilized arabinose to a final concentration of 0.02  (wv). Cultures were incubated for 1 h (37 qC, 
200 rpm) and 10 mL was removed from each (induced sample). The 10 mL cultures were harvested 
by centrifugation at 4,000 g for 10 min (4 qC). The cell pellets (uninduced and induced with arabinose) 
were resuspended in phosphate buffered saline (PBS, Dulbecco’s PBS, Sigma) to obtain an OD600 of 
5. For whole cell samples, 200 PL of the OD600   5 sample was combined with 200 PL PBS. 100 µL of 
6 u loading dye (150 mM Tris-HCl, pH 6.8, 300 mM DTT, 6  (vv) SDS, 0.3  (wv) bromophenol 
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blue) was then added. For soluble samples, 200 PL of the OD600   5 sample was combined with 200 
PL bacterial protein extraction reagent (ThermoFisher Scientific) and incubated with agitation for 10 
min. The sample was then centrifuged at 16,000 g for 30 min (4 qC) and 100 PL of 6 u loading dye 
was added to the supernatant. The mixtures were then incubated at 90 qC for 10 min.  
Protein samples were separated on an SDS PAGE gel (15  (vv) acrylamide, 0.4  (wv) bis-
acrylamide, 1 M Tris-HCl, pH 8.45, 0.1  (wv)  SDS) and were transferred to Amersham  
polyvinylidene fluoride membrane using a semi dry transfer apparatus (Bio-Rad Ltd). Blocking was 
performed for 3 h at room temperature using 5  (wv) milk powder in TBST (tris-buffered saline 
Tween; 20 mM Tris-HCl, 150 mM NaCl, 0.2  (vv) Tween-20). Membranes were incubated overnight 
with the anti-E-lactamase antibody (AB3738, Merck Millipore) diluted 1:5000 in 5  (wv) milk powder 
in TBST. The membranes were washed for 3 u 10 min in TBST. Membranes were then incubated with 
goat anti-rabbit IgG horseradish peroxidase conjugate (7074, New England Biolabs) diluted 1:10000 
in TBST. Membranes were then washed 3 u 10 min in TBST before incubation with SuperSignalTM 
western pico chemiluminescent substrate (Thermo Fisher Scientific). The emitted signal was detected 
with Amersham hyperfilm (GE Healthcare).  
 
hIAPP, rIAPP, AE40 and AE42 purification or acquisition 
Human and rat islet amyloid polypeptide were synthesized and purified as described previously54 and 
kindly provided by Dr. Ling-Hsien Tu and Prof. Dan Raleigh (Stony Brook University, New York, USA). 
Synthetic AE42 was purchased from Invitrogen, catalogue number 03-112. AE40 was expressed in E. 
coli and purified as described previously24.   

Ela-linker and Ela-hIAPP purification 
BL21 (DE3) E. coli cells were transformed with the relevant plasmid and a single colony from a fresh 
transformation was used to inoculate 250 mL of LB medium containing 10 PgmL tetracycline and 
incubated overnight at 37 qC with shaking at 200 rpm. 25 mL of overnight culture was then used to 
inoculate 10 u 1 L sterile LB containing 10 PgmL tetracycline. The cultures were incubated at 37 qC 
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with shaking (200 rpm) until an OD600 of 0.6 was reached. Protein expression was then induced by the 
addition of filter-sterilized arabinose to a final concentration of 0.2  (wv). Cultures were incubated at 
25qC, 200 rpm, for 16 h. Cells were harvested in a Stratos continuous-flow rotor centrifuge at 15,000 
rpm (HCT 22.300 Heraeus rotor). 
The periplasmic fraction was extracted using the following procedure in a cold room using chilled 
reagents. The cell pellet was carefully resuspended in 20 mM Tris-HCl pH 8.0, 20  (wv) sucrose (4 
mL of solution per gram of wet cell pellet). 1100 volume of 100 u protease inhibitor cocktail (100 mM 
phenylmethylsulphonyl fluoride, 200 mM benzamidine, dissolved in EtOH) was added. 40 PL 0.5 M 
EDTA (Sigma) and 40 PL hen egg white lysozyme (Sigma) (10 mgmL) were added per gram of wet 
cell pellet, and the sample left for 20 min on a shaker. 80 PL of 1 M MgCl2 (per gram of wet cell pellet) 
was added to the solution, and the cell suspension was centrifuged (20 min, 12,000 rpm, JA 25.50 
Beckman-Coulter rotor, 4 qC) before the supernatant was collected.  
The periplasmic fraction containing the E-lactamase construct was dialyzed overnight (3,500 MWCO 
membrane) against 5 L of 20 mM Tris-HCl, pH 7.5, 5 M urea at 4 qC with stirring. This process was 
repeated 3 times. The solution was filtered through a 0.2 Pm syringe filter (Sartorius Stedim Biotech). 
The dialyzed periplasmic fraction obtained from 10 L of cells was loaded onto a 5 mL Hi Trap Q HP 
anion exchange column connected to an ÄKTA prime (GE Healthcare), equilibrated with three column 
volumes of 20 mM Tris-HCl, pH 7.5, 5 M urea (buffer A). The column was washed with three column 
volumes of buffer A before the protein was eluted with a linear gradient of 0–0.5 M NaCl, 20 mM Tris-
HCl, pH 7.5, 5 M urea (Buffer B), maintaining the flow rate at 5 mLmin for all steps. 1.5 mL fractions 
were collected and the elution of protein monitored by absorbance at 280 nm. Fractions 
corresponding to the various peaks were analyzed by SDS PAGE. The fractions that contained the E-
lactamase construct were pooled for further purification.  
The desired fractions from anion exchange were concentrated to a final volume of 5 mL using an 
Amicon Ultra Centrifugal filter (10,000 MWCO). The sample (5 mL) was loaded onto a Superdex™ 75 
GL 10300 gel filtration column (GE Healthcare), which had been equilibrated with 250 mL of 20 mM 
Tris-HCl, pH 7.5, 5 M urea. The protein was eluted from the column at a flow rate of 2 mLmin. 1.5 mL 
fractions were collected and the elution of protein monitored by absorbance at 280 nm. Fractions 
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corresponding to the main peak were analyzed by SDS PAGE. The protein was refolded by dialysis 
into 200 mM ammonium acetate, pH 8 (typical yields from 1–2 mgL pure protein were obtained). 
Protein identity was confirmed by mass spectrometry and protein was stored at –80 qC. 
 
Thioflavin T fluorometry  
100 PL samples containing 100 PM thioflavin T and 50 PM protein in 200 mM ammonium acetate, pH 
6.8 and a 1  (vv) final concentration of DMSO were prepared in a 96-well plate (CoStar) and sealed 
with clear sealing film (Breathe Easy, Sigma). Plates were incubated in a FLUOstar OPTIMA plate 
reader for 5 days at 25 qC without agitation. Fluorescence was excited using a 440 r 5 nm filter, and 
emission intensity was measured using a 485 r 5 nm filter.  
 
In vitro E-lactamase enzyme assay 
The enzyme activity of Ela-linker and Ela-hIAPP was quantified spectrophotometrically using the 
colorimetric substrate nitrocefin. The assay was performed in a UV-1800 spectrophotometer 
(Shimadzu Ltd). In the absence of curcumin, 50 PL of 0.02 pmolPL Ela-linker or Ela-hIAPP (in 50 mM 
sodium phosphate buffer, pH 7) was transferred to a clean quartz cuvette with a 1 cm path-length 
(Hellma Analytics). The reaction was started by the addition of 50 PL nitrocefin (100 PM stock solution 
in 50 mM sodium phosphate buffer, pH 7, 5  (vv) DMSO). Samples were base-line corrected using 
50 PL of 50 mM sodium phosphate buffer, pH 7 with 50 PL nitrocefin stock. The change in absorbance 
at a wavelength of 486 nm was measured over 2 min at time intervals of 5 sec at room temperature. 
All determinations were carried out in triplicate. The initial rate of nitrocefin hydrolysis was calculated 
(using the known molar extinction co-efficient of hydrolyzed nitrocefin (H   20,500 M–1 cm–1)) and the 
specific activity was calculated as the amount of nitrocefin hydrolyzed per min per mg of enzyme (100 
 activity). 
In the presence of curcumin, the same assay conditions as above were used, however the enzyme 
stock solutions contained 0.2 pmolPL curcumin (to give a final molar ratio of curcumin: enzyme of 
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10:1). The base-line was corrected using 50 PL of 0.2 pmolPL curcumin in 50 mM sodium phosphate 
buffer, pH 7 and 50 PL nitrocefin stock.  
 
In vitro E-lactamase aggregation assay 
Ela-linker or Ela-hIAPP (in 50 mM sodium phosphate buffer, pH 7) was added to wells of a 96-well 
plate (CoStar) to give a final enzyme concentration of 32 PM. 3.2 PL of 10 mM curcumin (in 100  
DMSO) was added to give a final small molecule concentration of 320 PM. For assays in the absence 
of curcumin, 3.2 PL of DMSO was added instead. Solutions were made up to 100 PL with 50 mM 
sodium phosphate buffer, pH 7 and the plates sealed with transparent, hydrophobic and gas 
permeable plastic films (Breathe Easy, Sigma). Plates were incubated for 5 days (quiescent, 25 qC). 
After 5 days, the enzyme activity of the whole sample was measured using a final enzyme 
concentration of 0.01 pmolPL as described above. The samples were then centrifuged (1 h, 16,250 
rpm, F-45-12-11 Eppendorf USA rotor) and the concentration of protein remaining in solution 
determined by the absorbance at 280 nm and the molar extinction coefficient of Ela-linker (28,085 M–1 
cm–1) or Ela-hIAPP (29,700 M–1 cm–1) (samples were base-line corrected using 100 PL of 50 mM 
sodium phosphate buffer, pH 7, containing a final concentration of 320 PM curcumin, or an equivalent 
volume of DMSO). The enzyme assay was repeated and the amount of nitrocefin hydrolyzed per min 
mg of protein was calculated. The specific activity was calculated as a percentage of the initial 
specific activity (activity at t   0 was 100 ). 
 
Transmission electron microscopy 
Transmission electron microscope images were acquired on a JEOL JEM-1400 transmission electron 
microscope (JEOL Ltd.) after incubating 32 PM protein (Ela-linker, Ela-hIAPP, rIAPP, hIAPP, AE40, or 
AE42) solutions in the presence or absence of 320 PM small molecule for 5 days at 25 qC, quiescent. 
Carbon grids were prepared by irradiating under UV light for 30 min and samples were stained with 4 
 (wv) uranyl acetate (Sigma) solution.   
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Characterization of Ela-hIAPP aggregates as amyloid 
Fluorescence emission spectra of 50 PM Ela-linker, Ela-hIAPP or hIAPP (in 200 mM ammonium 
acetate, pH 6.8, 1  (vv) DMSO) were recorded after 5 days incubation by the addition of 10 PM of 
the amyloid-specific dyes NIAD-4 (ChemShuttle) or ThT (Sigma). Spectra were aquired using a 
Photon Technology International fluorimeter (Ford). NIAD-4 emission spectra were recorded between 
500 nm to 800 nm using an excitation wavelength of 490 nm with excitation and emission slit widths 
of 3 nm and 4 nm, respectively. ThT emission spectra were recorded between 460 nm and 800 nm 
using an excitation wavelength of 440 nm with excitation and emission slit widths of 2 nm and 3 nm, 
respectively. 
Dot-blots were performed using 10 PL of 50 PM of each protein incubated for 5 days, as described 
above. Proteins were transferred to Amersham nitrocellulose using a SCIE-PLAS dot-blotting 
manifold. Blocking was performed for 3 h at room temperature using 5  (wv) BSA in TBST. 
Membranes were incubated overnight with the anti-amyloid antibody WO1 (a gift from R. Wetzel, 
University of Pittsburgh, USA) diluted 1:5000 in 5  (wv) BSA in TBST or 5  (wv) BSA in TBST 
with no primary antibody as a control. The membranes were washed for 3 u 10 min in TBST. 
Membranes were then incubated with rat anti-mouse IgM horseradish peroxidase conjugate (BD 
Biosciences) diluted 1:7500 in TBST. Membranes were then washed 3 u 10 min in TBST before 
incubation with SuperSignalTM western pico chemiluminescent substrate (Thermo Fisher Scientific). 
The emitted signal was detected with Amersham hyperfilm (GE Healthcare).  
 
Mass spectrometry sample preparation 
Lyophilized hIAPP and rIAPP samples were dissolved in DMSO to a concentration of 3.2 mM. After 
24 h incubation at 25 qC, stock solutions were diluted in 200 mM ammonium acetate, pH 6.8, to give a 
final peptide concentration of 32 PM for mass spectrometry analysis. The final concentration of DMSO 
was 1  (vv). Lyophilized AE40 and AE42 were dissolved at 32 PM in 200 mM ammonium acetate, 
pH 6.8, 1  DMSO (vv). The AE40 and AE42 peptide samples were centrifuged (13,000 rpm, F-45-
12-11 Eppendorf USA rotor, 4 qC, 10 min) before analysis. All samples were incubated at 25 qC in 96-
well plates without agitation.  
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300 PM Ela-hIAPP or Ela-linker stock solution (in 200 mM ammonium acetate, pH 8) was buffer 
exchanged using 0.5 mL Zeba buffer exchange columns (Thermo Fischer Scientific) equilibrated with 
200 mM ammonium acetate, pH 6.8. The sample was diluted to a final concentration of 50 PM for 
mass spectrometry analysis.  
 
ESI-(IMS)-MS analysis  
A Synapt HDMS quadrupole-time-of-flight mass spectrometer (Waters Corpn.), equipped with a 
Triversa NanoMate (Advion Biosciences) automated nano-ESI interface, was used for the analyses. 
The instrument has a traveling-wave IMS device situated between the quadrupole and the time-of-
flight analyzers, and has been described in detail elsewhere55. rIAPP, hIAPP, AE40 or AE42 samples 
were analyzed using positive ionization nanoESI (nESI) with a capillary voltage of 1.7 kV and a 
nitrogen nebulizing gas pressure of 0.8 psi. The following instrumental parameters were used: cone 
voltage 30 V; source temperature 60 qC; backing pressure 1.6 mBar; ramped traveling wave height 7–
20 V; traveling wave speed 300 ms; IMS nitrogen gas flow 20 mLmin; IMS cell pressure 0.55 mBar. 
Data were processed by use of MassLynx v4.1 and Driftscope software supplied with the mass 
spectrometer. The mz scale was calibrated with aq. CsI cluster ions.  
For ESI-IMS-MS time course experiments, 50 PM peptide samples were incubated in 200 mM 
ammonium acetate buffer, pH 6.8, 1  (vv) DMSO for 2 min or 24 h. 10 PL volumes were removed 
from each solution and infused into the mass spectrometer for analysis. 
 
Mass spectrometry analysis of ligand binding to monomeric protein  
hIAPP (32 PM) in 200 mM ammonium acetate (pH 6.8) containing 320 PM of small molecule was 
analyzed by ESI-MS using a sampling cone voltage of 30 V to preserve protein-ligand interactions, 
and a backing pressure of 1.6 mBar. Data were acquired over the range mz 100–6,000, and 
processed by use of MassLynx v4.1 and Driftscope software supplied with the mass spectrometer. 
The mz scale was calibrated with aq. CsI cluster ions.  
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10 mM stock of small molecule (dissolved in DMSO, EtOH or H2O) was added to solutions of Ela-
linker or Ela-hIAPP (in 200 mM ammonium acetate, pH 6.8) to give a final small molecule: Ela-
linkerEla-hIAPP concentration of 500:50 PM. The following instrumental parameters were used: cone 
voltage 30 V; source temperature 60 qC; backing pressure 4.0 mBar; ramped traveling wave height 7–
20 V; traveling wave speed 300 ms; IMS nitrogen gas flow 20 mLmin; IMS cell pressure 0.55 mBar. 
 
Virtual screening for small molecules 
The structure of a recently identified inhibitor of hIAPP aggregation, JCS-1 (compound 36; 6-[4-(2-
fluorophenyl)-1-piperazinyl]-carbonyl-3-methyl-5H-[1,3]-thiazolo[3,2-a]pyrimidin-5-one)24, was 
minimized to the lowest energy conformer using LigPrep56. The minimized conformer was used as the 
query scaffold for virtual screening of an in-house library of 50,000 structurally diverse, novel small 
molecules using Rapid Overlay of Chemical Structures (ROCS)57. ROCS is a 3D method that 
matches the shape of a molecule to the shape of the query molecule. It also incorporates 
pharmacophoric features in assessing overlays such that the ROCS Combiscore measures the 
similarity of the matched shapes as well as the matched pharmacophoric features. Virtual hits were 
pooled and ranked according to the ROCS Combiscore parameter and 28 were selected for 
screening based on a qualitative assessment of structural diversity.  
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